Systematic determination of EGFR mutation (m) and immunohistochemistry (IHC) of ALK translocation (t) status in patients (p) with newly non-small cell lung cancer (NSCLC).

e22112 Background: Detection of EGFR m in p with NSCLC is done in a routine way. Given the data published on ALK positive p detection is crucial for therapeutic decision making. ALK t should be performed using FISH break apart probes for selecting p but probably is not enough quick for clinical wide use. Based on promising results IHC assay may be used as screening. We implemented a systematic determination of EGFR m and ALK t status to asses feasibility and accuracy in a clinical setting. Methods: We have tested all p with newly diagnosed NSCLC (non squamous or squamous with a light smoking history) from 12 centers. All samples were send to H. 12 de Octubre (June -December 2013). The objective was to evaluate the accuracy of EGFR m testing (TheraScreen/Cobas test) and ALK t testing. We performed IHC, as screening, using Ventana D5F3 mouse monoclonal antibody. P with positive IHC were checked using Abbot Vysis Break Apart. Results: 366 p were tested for EGFR/ALK simultaneously. 109 (29.78 %) were women an...